# China NMPA Drug Inspection - Hebei Honghan Pharmaceutical Co., Ltd. - Purple gromwell

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-honghan-pharmaceutical-co-ltd/707a28c8-9c56-451c-a39e-540eb6998fca/
Source feed: China

> China NMPA drug inspection for Hebei Honghan Pharmaceutical Co., Ltd. published September 15, 2022. Drug: Purple gromwell. In September 2022, the National Medical Products Administration (NMPA) issued Announcement No. 43, revealing that 17 bat

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 43 of 2022 from the National Medical Products Administration regarding 17 batches of drugs that did not meet the requirements.
- Company Name: Hebei Honghan Pharmaceutical Co., Ltd.
- Publication Date: 2022-09-15
- Drug Name: Purple gromwell
- Inspection Finding: Properties do not meet regulations
- Action Taken: Suspend sales and use, recall, conduct investigation and rectification, initiate investigation.
- Summary: In September 2022, the National Medical Products Administration (NMPA) issued Announcement No. 43, revealing that 17 batches of pharmaceutical products failed to meet national quality standards. The findings resulted from testing conducted by multiple institutions, including the Hubei Provincial Institute for Drug Control and the China National Institutes for Food and Drug Control. Fourteen companies were implicated, including Shanxi Guorun Pharmaceutical Co., Ltd., Hubei Tongdetang Pharmaceutical Co., Ltd., and several traditional medicine suppliers such as Shanghai Wanshicheng Pharmaceutical Co., Ltd. Main violations identified during the inspections included excessive hydrogen sulfide in acetylcysteine injections, improper methanol levels in Huoxiang Zhengqi Water, and prohibited pesticide residues in chrysanthemum samples. Other issues included failures in product appearance and identification for traditional root medicines. Operating under the Drug Administration Law of the People's Republic of China, the NMPA has mandated immediate risk control measures. The involved enterprises must suspend the sale and use of the non-compliant products and initiate formal recalls. Additionally, companies are required to investigate the root causes of these quality failures and implement comprehensive rectifications. Provincial regulatory authorities have been directed to investigate potential illegal activities and publicly disclose the results of their findings to ensure industry compliance and public safety.

Company: https://www.globalkeysolutions.net/companies/hebei-honghan-pharmaceutical-co-ltd/3964b796-4806-407a-bfaa-5b8f979341e1/